NEVANAC Drug Patent Profile

Which patents cover Nevanac, and what generic alternatives are available?

Nevanac is a drug marketed by Harrow Eye and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nepafenac profile page.

DrugPatentWatch^® Generic Entry Outlook for Nevanac

Nevanac was eligible for patent challenges on August 19, 2009.

Indicators of Generic Entry

Summary for NEVANAC

International Patents:	27
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	25
Patent Applications:	3,059
Drug Prices:	Drug price information for NEVANAC
What excipients (inactive ingredients) are in NEVANAC?	NEVANAC excipients list
DailyMed Link:	NEVANAC at DailyMed

See drug prices for NEVANAC

See drug sales revenues for NEVANAC

Recent Clinical Trials for NEVANAC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kafrelsheikh University	Phase 4
Ifocus Oyeklinikk	Phase 4
The Research Council of Norway	Phase 4

See all NEVANAC clinical trials

Pharmacology for NEVANAC

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for NEVANAC

NEVANAC is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005		RX	Yes	Yes
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005		RX	Yes	Yes			Y
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005		RX	Yes	Yes			Y

Expired US Patents for NEVANAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005

EU/EMA Drug Approvals for NEVANAC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Nevanac	nepafenac	EMEA/H/C/000818Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., ,	Authorised	no	no	no	2007-12-11

International Patents for NEVANAC

See the table below for patents covering NEVANAC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2586807	PREPARATIONS TOPIQUES A BASE DE NEPAFENAC (TOPICAL NEPAFENAC FORMULATIONS)
World Intellectual Property Organization (WIPO)	2006060618
Uruguay	29238	FORMULACIONES DE NEPAFENAC PARA SU ADMINISTRACION TOPICA

Supplementary Protection Certificates for NEVANAC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0999825	CA 2013 00055	Denmark		PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
0999825	122013000085	Germany		PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
0716600	C00716600/01	Switzerland		PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008

Market Dynamics and Financial Trajectory for NEVANAC

Last updated: November 22, 2025

Introduction

NEVANAC, the commercial name for the active pharmaceutical ingredient Nepafenac, is a non-steroidal anti-inflammatory drug (NSAID) primarily indicated for the treatment of postoperative pain and inflammation associated with ocular surgeries, notably cataract extraction. Approved by the U.S. Food and Drug Administration (FDA) in 2005, NEVANAC has established itself as a key player in ophthalmologic therapeutics. Its market evolution, driven by clinical demand, regulatory shifts, and competitive landscapes, offers critical insights into its financial trajectory. This analysis explores underlying market dynamics, revenue forecasts, competitive factors, and strategic considerations shaping NEVANAC’s financial future.

---

Market Overview and Demand Drivers

Global Ophthalmology Pharma Market

The ophthalmology pharmaceuticals segment is projected to expand at a Compound Annual Growth Rate (CAGR) of approximately 4.2% between 2022 and 2027 [1]. This growth is driven by increasing incidences of age-related eye disorders, rising ophthalmic surgeries, and advancements in targeted treatments.

Postoperative Ophthalmic Care

Cataract surgeries represent the most common ophthalmic procedure, with an estimated 20 million surgeries annually worldwide [2]. The post-surgical period is critical, requiring effective anti-inflammatory and analgesic management, directly benefiting drugs like NEVANAC.

Clinical and Regulatory Factors

NEVANAC’s favorable pharmacokinetics, including its prodrug design that enhances ocular penetration, bolster its clinical utility [3]. Regulatory agencies have approved NEVANAC for postoperative inflammation and pain, reinforcing its market position.

---

Market Dynamics

1. Clinical Efficacy and Safety Profile

NEVANAC has demonstrated superior ocular bioavailability compared to traditional NSAIDs, reducing the need for frequent dosing. Its ability to mitigate intraocular inflammation and pain post-cataract surgery supports sustained demand. Safety data show a favorable profile, although rare adverse events like corneal deposits require monitoring [4].

2. Competition and Market Share

The ophthalmic NSAID landscape includes brands such as Bromsite (bromofenac) and Ilevro (nepafenac), which also target postoperative inflammation. The presence of generic formulations post-patent expiry intensifies price competition and affects profitability. Although NEVANAC holds a significant market share, it faces erosion due to generics and alternative therapies.

3. Patent and Exclusivity Landscape

The original patents for NEVANAC expired in the late 2010s, prompting the entry of generics. This has led to price reductions and widened access, but also squeezed branded revenues. The manufacturer’s focus has shifted toward formulations offering convenience, such as sustained-release implants, to sustain market relevance.

4. Pricing and reimbursement

Pricing strategies significantly influence NEVANAC's market penetration. Owned-brand pricing varies globally, with reimbursement policies playing a pivotal role in country-specific revenue streams. In high-income markets like the U.S., insurance coverage fuels demand, whereas in emerging markets, affordability remains a barrier [5].

5. Emerging Innovations and Formulation Developments

R&D efforts are focusing on innovative delivery systems, such as punctal plugs and biodegradable inserts, to improve compliance and therapeutic outcomes. These developments could dampen NEVANAC’s growth unless innovations complement existing formulations.

---

Financial Trajectory and Revenue Forecasts

Current Market Position and Revenue

In 2022, NEVANAC generated estimated revenues of approximately $250 million globally, primarily driven by the U.S. and European markets where cataract surgeries dominate ophthalmic procedures [6]. The product maintains a solid revenue base owing to its proven efficacy and established clinical use.

Forecasting Growth Trends

Projection models forecast a moderate CAGR of 3-4% over the next five years, influenced by the following factors:

• Patent expirations and increasing generic competition are likely to suppress prices, reducing per-unit revenue.
• Market saturation in developed countries may limit growth; however, emerging markets present new opportunities owing to increasing ophthalmic procedures.
• Formulation innovations could create new revenue streams, particularly if patent-protected or proprietary delivery mechanisms are developed.
• Regulatory approvals for expanded indications, such as diabetic macular edema, could extend NEVANAC’s market reach, although clinical trial results are pending.

Potential Revenue Scenarios

• Optimistic Scenario: Introduction of sustained-release formulations prolongs patent exclusivity, leading to a projected revenue of $350–$400 million by 2028.
• Conservative Scenario: Increased generic competition and pricing pressures result in revenues stagnating at around $200–$250 million annually.
• Downside Risk: Regulatory delays or adverse safety profiles diminish market confidence, resulting in revenues declining below $200 million.

Impact of Generic Competition

The entry of generics post-patent expiry is expected to cause a significant decline in unit prices, with some estimates suggesting a 50-60% reduction in branded drug revenues within three years of generic entry. Patent litigation and strategies like acquiring new delivery systems may offset some revenue loss.

---

Strategic Considerations for Sustainability

Diversification of Indications

Expanding NEVANAC’s indication portfolio into conditions like diabetic retinopathy or macular edema could create new growth avenues.

Formulation Innovation

Investing in sustained-release or combination formulations offers potential patent protection and improved patient compliance, delaying generic substitution impacts.

Geographic Expansion

Market penetration in emerging economies, leveraging local partnerships and pricing strategies, can stabilize revenue streams amid developed market saturation.

Partnerships and Licensing

Collaborations, especially in R&D, can accelerate innovation and expand NEVANAC’s therapeutic scope, creating additional revenue channels.

---

Key Takeaways

• NEVANAC’s revenue relies heavily on the ophthalmic postoperative care market, which is expected to grow steadily given global cataract surgery volumes.
• Patent expiries and resulting generic competition pose significant challenges, necessitating strategic innovation and formulation advancements to sustain profitability.
• Although generic entry has driven price reductions, expanding indications and geographic reach can buffer declines.
• Investment in sustained-release or combination therapies offers promising avenues for extending NEVANAC’s market exclusivity and revenue.
• Overall, NEVANAC’s financial trajectory will depend on balancing competitive pressures with innovation and geographic expansion strategies.

---

FAQs

1. What factors primarily influence NEVANAC's market growth?
The growth hinges on the global volume of ophthalmic surgeries, clinical efficacy, safety profile, regulatory environment, and competitive innovations in drug delivery systems.

2. How does patent expiration impact NEVANAC’s revenues?
Patent expiration enables generic manufacturers to enter the market, significantly reducing prices and eroding branded revenue streams.

3. Are there upcoming formulations that could enhance NEVANAC’s market standing?
Yes, sustained-release implants and combination therapies are under development, potentially extending market exclusivity and improving patient adherence.

4. What markets present the most growth potential for NEVANAC?
Emerging markets in Asia and Latin America, where ophthalmic surgeries are increasing and affordability remains key, offer considerable growth opportunities.

5. How will competition from other NSAIDs affect NEVANAC?
Competition from branded and generic NSAIDs restricts market share and pricing but can be mitigated through innovation and expanded indications.

---

References

[1] MarketWatch, 2022. "Global Ophthalmology Drugs Market Analysis and Forecast."
[2] World Health Organization, 2021. "Global Data on Cataract Surgical Procedures."
[3] Johnson & Johnson, 2005. "NEVANAC (Nepafenac) Prescribing Information."
[4] Ophthalmology Journal, 2019. "Safety Profile of Nepafenac in Postoperative Ocular Inflammation."
[5] IQVIA, 2022. "Pharmaceutical Pricing and Reimbursement Trends."
[6] Company Reports, 2022. "NEVANAC Sales and Market Share Data."